WASHINGTON, July 17, 2026
The American Pharmacists Association (APhA) has called on the U.S. Food and Drug Administration (FDA) and the Pharmacy Compounding Advisory Committee (PCAC) to place patient safety, scientific evidence, and regulatory oversight at the center of their review of peptide substances proposed for inclusion on the Section 503A Bulks List. The organization warned that the rapid growth of unregulated peptide products sold through online and gray-market channels poses significant risks to public health, including contamination, inaccurate dosing, counterfeit ingredients, and potentially serious adverse events. In formal comments submitted to the FDA, APhA emphasized that while peptide-based medicines hold considerable therapeutic promise, regulatory decisions must be guided by robust clinical evidence rather than commercial demand. The association also reaffirmed the essential role of pharmacists in ensuring patients receive safe, high-quality compounded therapies when sufficient scientific evidence and regulatory standards are established.
APhA Warns of Growing Risks from Unregulated Peptide Market
According to APhA, the expanding availability of peptide products through unregulated online suppliers has created a rapidly growing market operating outside established pharmaceutical quality and safety standards. The association cautioned that patients purchasing these products may unknowingly expose themselves to contaminated formulations, inconsistent dosing, counterfeit ingredients, and unknown manufacturing practices that can result in serious health complications. Pharmacy leaders stressed that while innovation remains critical to advancing modern medicine, new therapies must be supported by peer-reviewed scientific research, rigorous manufacturing controls, and comprehensive regulatory oversight before they are widely available. APhA noted that pharmacists routinely witness the benefits of peptide-based medicines when they are produced under appropriate quality standards, reinforcing the need for evidence-based evaluation before expanding access to compounded peptide substances.
Limited Clinical Evidence Supports FDA’s Current Position
In its submission to the FDA, APhA stated that currently available evidence is insufficient for pharmacists to confidently counsel patients regarding many of the peptide substances under review. Significant knowledge gaps remain concerning clinical effectiveness, long-term safety, drug interactions, dosing considerations, and overall risk profiles. Given these uncertainties, the association expressed support for the FDA’s recommendation not to add the nominated peptide substances to the Section 503A Bulks List at this time. APhA emphasized that any future regulatory decision should be based on comprehensive clinical data demonstrating both safety and efficacy through rigorous scientific investigation. Until stronger evidence becomes available, pharmacists believe that patient protection should remain the primary consideration guiding federal regulatory decisions surrounding compounded peptide therapies.
Advertisement
Pharmacists Call for Stronger Oversight and Continued Research
Beyond its recommendations on the current review, APhA urged the FDA to strengthen educational initiatives for both healthcare professionals and patients regarding the safe use of peptide therapies. The organization also encouraged closer collaboration between the FDA, state boards of pharmacy, the United States Pharmacopeia (USP), and the pharmacy profession to improve quality standards, regulatory oversight, and public awareness. Continued investment in clinical research was identified as essential for establishing the long-term safety, effectiveness, and appropriate therapeutic role of peptide-based medicines. APhA reaffirmed that once sufficient evidence supports their clinical use, pharmacists will play a vital role in preparing high-quality compounded formulations, educating patients, monitoring treatment outcomes, and ensuring these therapies are dispensed through regulated pharmacy channels rather than unregulated online marketplaces. The association believes that maintaining strong scientific standards today will help foster safer innovation and better patient outcomes as peptide therapeutics continue to evolve.
Source: American Pharmacists Association press release
